ImmunoGen Inc (IMGN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ImmunoGen Inc (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9899
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The company’s lead product candidate, mirvetuximab soravtansine, a folate receptor alpha (FRa) intended for the treatment of platinum-resistant ovarian cancer and other types of solid tumors, and in Phase 1b/2 testing in combination regimens. Its other pipeline products include IMGN779, a CD33-targeting product candidate for acute myeloid leukemia (AML); and IMGN632 for AML, B-cell acute lymphocytic leukemia, myelodysplastic syndrome and other CD123-positive malignancies. It also carries out early state programs in the areas of solid and liquid tumors. The company has partnership with various pharmaceutical companies to develop and commercialize anticancer compounds. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc (IMGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12
ImmunoGen Enters into Research Agreement with Merck 13
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15
Licensing Agreements 17
Takeda Enters into Licensing Agreement with ImmunoGen 17
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19
Equity Offering 20
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 25
Debt Offering 27
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27
Asset Transactions 28
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29
ImmunoGen Inc – Key Competitors 30
ImmunoGen Inc – Key Employees 31
ImmunoGen Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 02, 2018: ImmunoGen reports recent progress and third quarter 2018 operating results 33
Jul 27, 2018: ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results 35
May 04, 2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results 37
Feb 09, 2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results 39
Nov 03, 2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results 41
Jul 28, 2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results 43
May 05, 2017: ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results 45
Feb 17, 2017: ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016 47
Corporate Communications 49
Apr 25, 2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer 49
Jan 23, 2017: ImmunoGen Announces Departure of Sandra Poole 50
Product News 51
03/14/2018: ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
ImmunoGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12
ImmunoGen Enters into Research Agreement with Merck 13
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15
Takeda Enters into Licensing Agreement with ImmunoGen 17
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 25
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29
ImmunoGen Inc, Key Competitors 30
ImmunoGen Inc, Key Employees 31
ImmunoGen Inc, Subsidiaries 32

List of Figures
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ImmunoGen Inc (IMGN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rompetrol Rafinare SA (RRC):企業の財務・戦略的SWOT分析
    Rompetrol Rafinare SA (RRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • AEON Credit Service (Asia) Co., Ltd.:企業の戦略・SWOT・財務情報
    AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Oxford Biodynamics Plc:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • TenneT Holding BV:電力:M&Aディール及び事業提携情報
    Summary TenneT Holding BV (TenneT), owned by the Ministry of Finance of The State of the Netherlands, is an electricity transmission system operator. The company offers electricity transmission and system services. It constructs and maintains high voltage grid to transmit electricity from the produc …
  • Koninklijke Ahold Delhaize NV (AD):企業の財務・戦略的SWOT分析
    Koninklijke Ahold Delhaize NV (AD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Trafigura Group Pte Ltd:企業の戦略的SWOT分析
    Trafigura Group Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Invenergy LLC:企業の発電所・SWOT分析2018
    Invenergy LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Xped Limited (XPE)-石油・ガス分野:企業M&A・提携分析
    Summary Xped Limited (Xped) formerly Raya Group Limited, is an Internet of Things company that develops software and hardware solutions. It offers auto discovery remote control, Xerts, and Xped app software; and hardware such as Xped ADRC Shields, Umbo-Xped ADRC Hub, UltraPlug, VariPlug, IRBlaster. …
  • Anaren, Inc.:戦略・SWOT・企業財務分析
    Anaren, Inc. - Strategy, SWOT and Corporate Finance Report Summary Anaren, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • PledPharma AB (PLED):企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Stanford University:企業のM&A・事業提携・投資動向
    Stanford University - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stanford University Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Tidewater Midstream and Infrastructure Ltd (TWM):石油・ガス:M&Aディール及び事業提携情報
    Summary Tidewater Midstream and Infrastructure Ltd (Tidewater Midstream) is a midstream and infrastructure company. It is involved in purchasing, sale and transportation of NGLs and export to overseas markets. The company engaged in selective acquisitions, organic growth projects, and optimization o …
  • Energen Corporation:企業の戦略・SWOT・財務情報
    Energen Corporation - Strategy, SWOT and Corporate Finance Report Summary Energen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Vermillion Inc (VRML):企業の財務・戦略的SWOT分析
    Summary Vermillion Inc (Vermillion) is a medical device company that discovers, develops and markets diagnostic and bio-analytical solutions that supports physicians to diagnose, treat and improve gynecologic health outcomes for women. The company’s in vitro diagnostic test OVA1, a simple blood test …
  • Systematic A/S:企業の戦略・SWOT・財務分析
    Systematic A/S - Strategy, SWOT and Corporate Finance Report Summary Systematic A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cimentos de Portugal SGPS SA:企業の戦略的SWOT分析
    Cimentos de Portugal SGPS SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • EZCORP Inc (EZPW):企業の財務・戦略的SWOT分析
    EZCORP Inc (EZPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Larsen & Toubro Ltd (LT):企業の財務・戦略的SWOT分析
    Larsen & Toubro Ltd (LT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sequana Medical AG:医療機器:M&Aディール及び事業提携情報
    Summary Sequana Medical AG (Sequana Medical), formerly NovaShunt AG, is a commercial stage medical device company that offers automated implantable pump systems to monitor fluid balance within the body. The company designs, develops and commercializes alfapump, a fully implantable, programmable, tra …
  • Nippon Sheet Glass Co Ltd:戦略・SWOT・企業財務分析
    Nippon Sheet Glass Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nippon Sheet Glass Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆